Just when you thought it was safe to talk on your cell phone.

Now some scientists say there is a chance that talking on a mobile phone for as little as 10 minutes could trigger changes in the brain that are associated with cancer, according to a story published on Thursday by the The Daily Mail.

LinkEvery thing gives you cancer..... There's no cure...there's no answer...NEW METHOD HELPS ATTACK CANCER CELLS
By HAROLD M. SCHMECK JR., SPECIAL TO THE NEW YORK TIMES
Rest of Article on http://query.nytimes.com/gst/fullpage.html?sec=health&res=9D01EEDD133BF932A0575BC0A967948260

The 67-year-old man had lymphoma, a form of cancer. The disease was tightening its grip, attacking his skin and his lymphatic system. Chemicals and radiation were failing.

Then his doctors started a new treatment with substances CALLED monoclonal antibodies designed to seek out his cancer cells exclusively and help kill them. These special antibodies, the most potent biological ''guided missiles'' known to science, were given repeatedly while the doctors watched for signs of dangerous toxicity from the new treatment. There were no such signs.

By the end of four weeks the man was looking better and feeling better. Some tumors on his skin disappeared; others became soft and flat, signs that they were being attacked. The patient's fevers and night sweats ceased. A medical REPORT described the response as encouraging.

A Pioneer Case

But this story does not have a happy ending. The patient's partial remission lasted about seven weeks; then the cancer advanced again and four weeks later the man died.

The case is significant, however, as a demonstration that effects can be achieved through such a guided-missile attack on cancer and as one of the first known USES of monoclonal antibodies in treatment of human illness.

Antibodies are defensive proteins produced by the body to help repel invasions of almost any foreign substance. Monoclonal antibodies are produced with the aid of special cell-fusion techniques that give rise to groups of extremely uniform antibodies that are much more selective than ordinary antibodies.

The case is also NOTABLE as an illustration of how implacably cancer can counterattack the most ingenious assaults of medical science. But the war is not over and the use of monoclonal antibodies to learn more of cancer's complex secrets and attack its outlaw cells is being pursued in animal research at many institutions and in humans at a few.

These efforts underscore the ever-broadening usefulness of these special antibodies that were not available to most scientists for any purpose until the last few years. Monoclonal antibodies have already had a major impact on many areas of scientific research and biochemical analysis. They have spawned an industry devoted to their production and use.

They show promise of speeding the development of vaccines against malaria, schistosomiasis and possibly other globally important parasite diseases; of permitting life-saving diagnosis of some infections in newborn babies, and of other uses, including the experimental treatment of a few carefully selected cancer patients.

Specialists note that it is still too early to say how useful monoclonal antibodies will be in treating any human malignancy. But, like other experimental weapons against cancer, they are already providing new insights into the nature of that complex group of diseases.

The 67-year-old man, who had a form of lymphoma called mycosis fungoides, was treated at the Stanford University Medical Center. His case was reported in a ''preliminary communication'' in The Lancet, the international medical journal, earlier this month by Drs. Richard A. Miller and Ronald Levy.

''Monoclonal antibody produced a striking clinical response in skin, lymph nodes, and blood, but complete remission was not achieved,'' their report said.

''We are encouraged by the results in this patient,'' they added. ''Perhaps antibodies of better specificity or more suitable class can be developed for treatment.''

Altogether, doctors at Stanford have tried monoclonal antibodies in eight cancer patients, two of them under treatment now. To date there has been no evidence of ill effects and there have been some encouraging results in at least four of the patients. Dr. Levy sees little hope that the special antibodies will ever cure cancers unaided, but he hopes they can be forged into a powerful weapon to aid other forms of treatment. Similar Methods in Boston

Similar strategies have been used on at least six patients by a group at Harvard's Sidney Farber Cancer Institute and the Children's hospital in Boston.